Pain Therapeutics Awarded $1.5 Million Research Grant by National Institutes of Health Life Science Investing
Aptinyx Reports Top-line Results from Phase 2 Clinical Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy Pharmaceutical Investing
FDA Grants Cerecor’s Three Substrate Replacement Therapies Orphan Drug Designation Pharmaceutical Investing
Stemline Therapeutics Announces Upsizing and Pricing of $80 Million Public Offering of Common Stock Pharmaceutical Investing
Menlo Therapeutics’ Serlopitant Granted Breakthrough Therapy Designation by FDA Life Science Investing
European Medicines Agency validates Oasmia Pharmaceutical AB’s application to add efficacy data to the approved Apealea Life Science Investing
ASLAN Pharmaceuticals to Present Positive varlitinib Data in First-Line Biliary Tract Cancer in Combination With Chemotherapy at ASCO GI Pharmaceutical Investing
ASLAN Pharmaceuticals Announces Study Results from Phase 2 Study of Varlitinib in First-line Gastric Cancer Life Science Investing
